SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-181680"
 

Sökning: id:"swepub:oai:DiVA.org:liu-181680" > TheraPearl Eye Mask...

TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction : a randomized, comparative clinical trial

Olafsson, Jonatan (författare)
Univ Oslo, Norway; Oslo Univ Hosp, Norway
Lai, Xiaoran (författare)
Univ Oslo, Norway
Landsend, Erlend Christoffer Sommer (författare)
Oslo Univ Hosp, Norway
visa fler...
Olafsson, Snorri (författare)
Innlandet Hosp Trust, Norway; Loma Linda Univ, CA 92354 USA
Parissi, Eric (författare)
Lavista Optometry, Norway
Utheim, Oygunn A. (författare)
Univ Oslo, Norway; Oslo Univ Hosp, Norway; Norwegian Dry Eye Clin, Norway
Raeder, Sten (författare)
Univ Oslo, Norway; Norwegian Dry Eye Clin, Norway
Badian, Reza A. (författare)
Oslo Univ Hosp, Norway; Norwegian Dry Eye Clin, Norway; Univ Southeast Norway, Norway
Lagali, Neil (författare)
Linköpings universitet,Avdelningen för sinnesorgan och kommunikation,Medicinska fakulteten,Region Östergötland, Ögonkliniken US,Sorlandet Hosp Arendal, Norway
Dartt, Darlene A. (författare)
Harvard Med Sch, MA 02114 USA
Utheim, Tor P. (författare)
Oslo Univ Hosp, Norway; Norwegian Dry Eye Clin, Norway; Oslo Univ Hosp, Norway; Univ Southeast Norway, Norway; Sorlandet Hosp Arendal, Norway; Stavanger Univ Hosp, Norway
visa färre...
 (creator_code:org_t)
2021-11-17
2021
Engelska.
Ingår i: Scientific Reports. - : Nature Portfolio. - 2045-2322. ; 11:1
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Meibomian gland dysfunction (MGD) is the most common cause of dry eye disease (DED). In this study, we aimed to compare the effects of eyelid warming treatment using either TheraPearl Eye Mask (Bausch & Lomb Inc., New York, USA) or Blephasteam (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK) in a Norwegian population with mild to moderate MGD-related DED. An open label, randomized comparative trial with seventy patients (49 females, 21 males; mean age 53.6 years). Patients were randomly assigned to treatment with Blephasteam (n = 37) or TheraPearl (n = 33). All received a hyaluronic acid based artificial tear substitute (Hylo-Comod, Ursapharm, Saarbrucken, Germany). Patients were examined at baseline, and at three and six months initiation of treatment. Treatment efficacy was primarily evaluated by fluorescein breakup time (FBUT) and Ocular Surface Disease Index (OSDI) scores. Other outcome measures included ocular surface staining (OSS), Schirmers test, and meibomian quality and expressibility. Baseline parameter values did not differ between the groups. After six months of treatment, Blephasteam improved FBUT by 3.9 s (p < 0.01) and OSDI by 13.7 (p < 0.01), TheraPearl improved FBUT by 2.6 s (p < 0.01) and OSDI by 12.6 (p < 0.01). No difference between treatments was detected at 6 months (p = 0.11 for FBUT and p = 0.71 for OSDI), nor were there differences in the other tested parameters between the treatment groups. Blephasteam and TheraPearl are equally effective in treating mild to moderate MGD in a Norwegian population after 6-months of treatment. Clinicaltrials.gov ID: NCT03318874; Protocol ID: 2014/1983; First registration: 24/10/2017.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy